Literature DB >> 32537177

Systematic review: measurement properties of patient-reported outcome measures evaluated with childhood brain tumor survivors or other acquired brain injury.

Kim S Bull1, Samantha Hornsey2, Colin R Kennedy1, Anne-Sophie E Darlington3, Martha A Grootenhuis4, Darren Hargrave5,6, Christina Liossi7,8, Jonathan P Shepherd9, David A Walker10, Christopher Morris11.   

Abstract

BACKGROUND: Survivors of childhood brain tumors or other acquired brain injury (ABI) are at risk of poor health-related quality of life (HRQoL); its valid and reliable assessment is essential to evaluate the effect of their illness on their lives. The aim of this review was to critically appraise psychometric properties of patient-reported outcome measures (PROMs) of HRQoL for these children, to be able to make informed decisions about the most suitable PROM for use in clinical practice.
METHODS: We searched MEDLINE, EMBASE, and PsycINFO for studies evaluating measurement properties of HRQoL PROMs in children treated for brain tumors or other ABI. Methodological quality of relevant studies was evaluated using the consensus-based standards for the selection of health status measurement instruments checklist.
RESULTS: Eight papers reported measurement properties of 4 questionnaires: Health Utilities Index (HUI), PedsQL Core and Brain Tumor Modules, and Child and Family Follow-up Survey (CFFS). Only the CFFS had evidence of content and structural validity. It also demonstrated good internal consistency, whereas both PedsQL modules had conflicting evidence regarding this. Conflicting evidence regarding test-retest reliability was reported for the HUI and PedsQL Core Module only. Evidence of measurement error/precision was favorable for HUI and CFFS and absent for both PedsQL modules. All 4 PROMs had some evidence of construct validity/hypothesis testing but no evidence of responsiveness to change.
CONCLUSIONS: Valid and reliable assessment is essential to evaluate impact of ABI on young lives. However, measurement properties of PROMs evaluating HRQoL appropriate for this population require further evaluation, specifically construct validity, internal consistency, and responsiveness to change.
© The Author(s) 2019. Published by Oxford University Press on behalf of the Society for Neuro-Oncology and the European Association of Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  acquired brain injury; brain tumor; children; patient-reported outcomes; systematic review

Year:  2019        PMID: 32537177      PMCID: PMC7274179          DOI: 10.1093/nop/npz064

Source DB:  PubMed          Journal:  Neurooncol Pract        ISSN: 2054-2577


  45 in total

Review 1.  The Health Utilities Index (HUI) system for assessing health-related quality of life in clinical studies.

Authors:  W J Furlong; D H Feeny; G W Torrance; R D Barr
Journal:  Ann Med       Date:  2001-07       Impact factor: 4.709

2.  The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes.

Authors:  Lidwine B Mokkink; Caroline B Terwee; Donald L Patrick; Jordi Alonso; Paul W Stratford; Dirk L Knol; Lex M Bouter; Henrica C W de Vet
Journal:  J Clin Epidemiol       Date:  2010-07       Impact factor: 6.437

3.  PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations.

Authors:  J W Varni; M Seid; P S Kurtin
Journal:  Med Care       Date:  2001-08       Impact factor: 2.983

4.  The PedsQL Brain Tumor Module: initial reliability and validity.

Authors:  Stephanie N Palmer; Kathleen A Meeske; Ernest R Katz; Tasha M Burwinkle; James W Varni
Journal:  Pediatr Blood Cancer       Date:  2007-09       Impact factor: 3.167

5.  Framework to assess the effects of using patient-reported outcome measures in chronic care management.

Authors:  Maria-Jose Santana; David Feeny
Journal:  Qual Life Res       Date:  2013-12-07       Impact factor: 4.147

6.  Finding out what matters: validity of quality of life measurement in young people with ASD.

Authors:  L Tavernor; E Barron; J Rodgers; H McConachie
Journal:  Child Care Health Dev       Date:  2012-04-20       Impact factor: 2.508

Review 7.  A systematic review of generic multidimensional patient-reported outcome measures for children, part II: evaluation of psychometric performance of English-language versions in a general population.

Authors:  Astrid Janssens; Morwenna Rogers; Jo Thompson Coon; Karen Allen; Colin Green; Crispin Jenkinson; Alan Tennant; Stuart Logan; Christopher Morris
Journal:  Value Health       Date:  2015-03       Impact factor: 5.725

8.  Health and persistent functional late effects in adult survivors of childhood CNS tumours: a population-based cohort study.

Authors:  K K Boman; E Hovén; M Anclair; B Lannering; G Gustafsson
Journal:  Eur J Cancer       Date:  2009-07-16       Impact factor: 9.162

9.  Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial.

Authors:  Galina Velikova; Laura Booth; Adam B Smith; Paul M Brown; Pamela Lynch; Julia M Brown; Peter J Selby
Journal:  J Clin Oncol       Date:  2004-02-15       Impact factor: 44.544

Review 10.  Measurement properties of multidimensional patient-reported outcome measures in neurodisability: a systematic review of evaluation studies.

Authors:  Astrid Janssens; Morwenna Rogers; Rebecca Gumm; Crispin Jenkinson; Alan Tennant; Stuart Logan; Christopher Morris
Journal:  Dev Med Child Neurol       Date:  2015-12-11       Impact factor: 5.449

View more
  2 in total

Review 1.  Childhood Malignant Brain Tumors: Balancing the Bench and Bedside.

Authors:  Colin Thorbinson; John-Paul Kilday
Journal:  Cancers (Basel)       Date:  2021-12-03       Impact factor: 6.639

2.  Childhood brain tumors: It is the child's brain that really matters.

Authors:  David A Walker
Journal:  Front Oncol       Date:  2022-10-04       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.